BACKGROUND AND PURPOSE: Given the crucial role of the skeletal muscle chloride conductance (gCl), supported by the voltage-gated chloride channel CLC-1, in controlling muscle excitability, the availability of ligands modulating CLC-1 are of potential medical as well as toxicological importance. Here, we focused our attention on niflumic acid (NFA), a molecule belonging to the fenamates group of non-steroidal anti-inflammatory drugs (NSAID). EXPERIMENTAL APPROACH: Rat muscle Cl(-) conductance (gCl) and heterologously expressed CLC-1 currents were evaluated by means of current-clamp (using two-microelectrodes) and patch-clamp techniques, respectively. Fura-2 fluorescence was used to determine intracellular calcium concentration, [Ca(2+)](i), in native muscle fibres. KEY RESULTS: NFA inhibited native gCl with an IC(50) of 42 muM and blocked CLC-1 by interacting with an intracellular binding site. Additionally, NFA increased basal [Ca(2+)](i) in myofibres by promoting a mitochondrial calcium efflux that was not dependent on cyclooxygenase or CLC-1. A structure-activity study revealed that the molecular conditions that mediate the two effects are different. Pretreatment with the Ca-dependent protein kinase C (PKC) inhibitor chelerythrine partially inhibited the NFA effect. Therefore, in addition to direct channel block, NFA also inhibits gCl indirectly by promoting PKC activation. CONCLUSIONS AND IMPLICATIONS: These cellular effects of NFA on skeletal muscle demonstrate that it is possible to modify CLC-1 and consequently gCl directly by interacting with channel proteins and indirectly by interfering with the calcium-dependent regulation of the channel. The effect of NFA on mitochondrial calcium stores suggests that NSAIDs, widely used drugs, could have potentially dangerous side-effects.
BACKGROUND AND PURPOSE: Given the crucial role of the skeletal muscle chloride conductance (gCl), supported by the voltage-gated chloride channel CLC-1, in controlling muscle excitability, the availability of ligands modulating CLC-1 are of potential medical as well as toxicological importance. Here, we focused our attention on niflumic acid (NFA), a molecule belonging to the fenamates group of non-steroidal anti-inflammatory drugs (NSAID). EXPERIMENTAL APPROACH: Rat muscle Cl(-) conductance (gCl) and heterologously expressed CLC-1 currents were evaluated by means of current-clamp (using two-microelectrodes) and patch-clamp techniques, respectively. Fura-2 fluorescence was used to determine intracellular calcium concentration, [Ca(2+)](i), in native muscle fibres. KEY RESULTS: NFA inhibited native gCl with an IC(50) of 42 muM and blocked CLC-1 by interacting with an intracellular binding site. Additionally, NFA increased basal [Ca(2+)](i) in myofibres by promoting a mitochondrial calcium efflux that was not dependent on cyclooxygenase or CLC-1. A structure-activity study revealed that the molecular conditions that mediate the two effects are different. Pretreatment with the Ca-dependent protein kinase C (PKC) inhibitor chelerythrine partially inhibited the NFA effect. Therefore, in addition to direct channel block, NFA also inhibits gCl indirectly by promoting PKC activation. CONCLUSIONS AND IMPLICATIONS: These cellular effects of NFA on skeletal muscle demonstrate that it is possible to modify CLC-1 and consequently gCl directly by interacting with channel proteins and indirectly by interfering with the calcium-dependent regulation of the channel. The effect of NFA on mitochondrial calcium stores suggests that NSAIDs, widely used drugs, could have potentially dangerous side-effects.
Authors: Sabata Pierno; Jean-François Desaphy; Antonella Liantonio; Michela De Bellis; Gianpatrizio Bianco; Annamaria De Luca; Antonio Frigeri; G Paola Nicchia; Maria Svelto; Claude Léoty; Alfred L George; Diana Conte Camerino Journal: Brain Date: 2002-07 Impact factor: 13.501
Authors: Ami Mankodi; Masanori P Takahashi; Hong Jiang; Carol L Beck; William J Bowers; Richard T Moxley; Stephen C Cannon; Charles A Thornton Journal: Mol Cell Date: 2002-07 Impact factor: 17.970
Authors: G Zifarelli; A Liantonio; A Gradogna; A Picollo; G Gramegna; M De Bellis; A R Murgia; E Babini; D Conte Camerino; M Pusch Journal: Br J Pharmacol Date: 2010-08 Impact factor: 8.739
Authors: Jennifer E Stanich; Simon J Gibbons; Seth T Eisenman; Michael R Bardsley; Jason R Rock; Brian D Harfe; Tamas Ordog; Gianrico Farrugia Journal: Am J Physiol Gastrointest Liver Physiol Date: 2011-09-22 Impact factor: 4.052
Authors: C Altamura; G F Mangiatordi; O Nicolotti; D Sahbani; A Farinato; F Leonetti; M R Carratù; D Conte; J-F Desaphy; P Imbrici Journal: Br J Pharmacol Date: 2018-04-06 Impact factor: 8.739
Authors: Anna Cozzoli; Antonella Liantonio; Elena Conte; Maria Cannone; Ada Maria Massari; Arcangela Giustino; Antonia Scaramuzzi; Sabata Pierno; Paola Mantuano; Roberta Francesca Capogrosso; Giulia Maria Camerino; Annamaria De Luca Journal: Am J Physiol Cell Physiol Date: 2014-07-30 Impact factor: 4.249